Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that TESTIN may represent a candidate tumor suppressor gene at 7q31.2.
|
10950921 |
2000 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We believe that TES is a tumour suppressor gene that is inactivated primarily by transcriptional silencing resulting from CpG island methylation.
|
11420696 |
2001 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results show that CAV1, CAV2, and TESTIN are not tumor suppressor genes in this gastric cancer.
|
12620387 |
2003 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TRG is located in an intron of the putative tumor suppressor gene Testin in the common fragile site 7G region at 7q31.2.
|
14579264 |
2003 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our immunohistochemical results and previously published data on the compartmental expression of these messenger RNAs in stromal and epithelial cells suggest that TES is the best candidate tumor suppressor gene at 7q31.
|
15252854 |
2004 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, TES expression significantly reduced the tumorigenic potential of both T47D and MES-SA in nude mice, whereas the untreated cells and Ad-GFP-infected cells showed tumor growth in vivo.
|
15701871 |
2005 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Two genes identified in this manner, RUNX3 and Testin (TES), were subsequently shown to harbor frequent tumor-specific epigenetic alterations in primary glioblastomas.
|
16909125 |
2007 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene array and siRNA experiments support that the cyclin-dependent kinase inhibitor p27 and the tumour suppressor gene testin are candidate JunD targets in cannabinoid action.
|
18454173 |
2008 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that the TES gene functions as a tumor suppressor gene and is frequently silenced by hypermethylation and loss of heterozygosity in ovarian cancers.
|
20180808 |
2010 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Down regulation of TES was shown to be correlated with tumor differentiation (p = 0.035) and prognosis (p = 0.035, log-rank test).
|
20626849 |
2010 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To explore the possible tumor suppressing function of TES, the expression of TES in breast cancer cells was manipulated by ectopic expression or by RNAi.
|
22957844 |
2012 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
GiPSCs and their differentiating derivatives display widespread resetting of common GBM-associated changes, such as DNA hypermethylation of promoter regions of the cell motility regulator TES (testis-derived transcript), the tumor suppressor cyclin-dependent kinase inhibitor 1C (CDKN1C; p57KIP2), and many polycomb-repressive complex 2 (PRC2) target genes (e.g., SFRP2).
|
23512659 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Testin (TES) is a putative tumour-suppressor gene downregulated in various types of cancers.
|
23715752 |
2013 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Moreover, TES hypermethylation was significantly correlated with larger tumor diameter (P=0.03) and lympho node metastasis (P=0.024).
|
25119600 |
2014 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Moreover, TESTIN hypermethylation was significantly correlated with advanced tumor stage, deep myometrial invasion and lymphatic node metastasis.
|
25720371 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, we investigated the function of the candidate tumor-suppressor Testin gene in non-small cell lung cancer (NSCLC).
|
28000866 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The focal adhesion protein testin is a modular scaffold and tumour suppressor that consists of an N-terminal cysteine rich (CR) domain, a PET domain of unknown function and three C-terminal LIM domains.
|
28542564 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Latest reports indicate that TES is a tumor suppressor gene which can contribute to cancerogenesis but the mechanism of loss TES gene expression is still unknown.
|
30357755 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Each domain of the COMMON-LE (pain, ADL, socioemotional condition and general health) was well correlated with the scores of the standard measures (SF-36, TESS, MSTS score).
|
30446332 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We explored the tumor suppressive effect of TES in GC by in vitro cell proliferation assay, colony formation assay, cell cycle analysis, Transwell assays, and in vivo tumorigenicity and metastasis assays.
|
30728082 |
2019 |